Literature DB >> 22596288

Predictors of morbidity and mortality in acromegaly: an Italian survey.

M Arosio1, G Reimondo, E Malchiodi, P Berchialla, A Borraccino, L De Marinis, R Pivonello, S Grottoli, M Losa, S Cannavò, F Minuto, M Montini, M Bondanelli, E De Menis, C Martini, G Angeletti, A Velardo, A Peri, M Faustini-Fustini, P Tita, F Pigliaru, G Borretta, C Scaroni, N Bazzoni, A Bianchi, M Appetecchia, F Cavagnini, G Lombardi, E Ghigo, P Beck-Peccoz, A Colao, M Terzolo.   

Abstract

OBJECTIVE: To describe demographic and hormonal characteristics, comorbidities (diabetes mellitus and hypertension), therapeutic procedures and their effectiveness, as well as predictors of morbidity and mortality in a nationwide survey of Italian acromegalic patients.
DESIGN: Retrospective multicenter epidemiological study endorsed by the Italian Society of Endocrinology and performed in 24 tertiary referral Italian centers. The mean follow-up time was 120 months.
RESULTS: A total of 1512 patients, 41% male, mean age: 45±13 years, mean GH: 31±37 μg/l, IGF1: 744±318 ng/ml, were included. Diabetes mellitus was reported in 16% of cases and hypertension in 33%. Older age and higher IGF1 levels at diagnosis were significant predictors of diabetes and hypertension. At the last follow-up, 65% of patients had a controlled disease, of whom 55% were off medical therapy. Observed deaths were 61, with a standardized mortality ratio of 1.13 95% (confidence interval (CI): 0.87-1.46). Mortality was significantly higher in the patients with persistently active disease (1.93; 95% CI: 1.34-2.70). Main causes of death were vascular diseases and malignancies with similar prevalence. A multivariate analysis showed that older age, higher GH at the last follow-up, higher IGF1 levels at diagnosis, malignancy, and radiotherapy were independent predictors of mortality.
CONCLUSIONS: Pretreatment IGF1 levels are important predictors of morbidity and mortality in acromegaly. The full hormonal control of the disease, nowadays reached in the majority of patients with modern management, reduces greatly the disease-related mortality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22596288     DOI: 10.1530/EJE-12-0084

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  61 in total

Review 1.  The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'.

Authors:  Saptarshi Bhattacharya; Sanjay Kalra; Deep Dutta; Deepak Khandelwal; Rajiv Singla
Journal:  Eur Endocrinol       Date:  2019-10-18

2.  Left ventricular synchronicity in acromegaly.

Authors:  Ludovica F S Grasso; Annamaria Colao
Journal:  Endocrine       Date:  2013-06-27       Impact factor: 3.633

3.  ACROSTUDY: the Italian experience.

Authors:  S Grottoli; P Maffei; F Bogazzi; S Cannavò; A Colao; E Ghigo; R Gomez; E Graziano; M Monterubbianesi; P Jonsson; L De Marinis
Journal:  Endocrine       Date:  2014-08-23       Impact factor: 3.633

4.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

Review 5.  Diabetes in Patients With Acromegaly.

Authors:  A M Hannon; C J Thompson; M Sherlock
Journal:  Curr Diab Rep       Date:  2017-02       Impact factor: 4.810

6.  Coagulation parameters and platelet function analysis in patients with acromegaly.

Authors:  A Colak; H Yılmaz; Y Temel; M Demirpence; N Simsek; İ Karademirci; U Bozkurt; E Yasar
Journal:  J Endocrinol Invest       Date:  2015-06-06       Impact factor: 4.256

7.  Impact of acromegaly treatment on cardiovascular complications.

Authors:  Adriana G Ioachimescu
Journal:  Endocrine       Date:  2017-02-03       Impact factor: 3.633

8.  Clinical features and therapeutic outcomes of acromegaly during the recent 10 years in a single institution in Japan.

Authors:  Izumi Fukuda; Naomi Hizuka; Toko Muraoka; Makiko Kurimoto; Yu Yamakado; Kazue Takano; Atsuhiro Ichihara
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

Review 9.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

10.  Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients.

Authors:  Orsalia Alexopoulou; Marie Bex; Peter Kamenicky; Augustine Bessomo Mvoula; Philippe Chanson; Dominique Maiter
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.